来源：Gangtise投研

　　兆科眼科（06622.HK） 2024年全年业绩投资者交流会：2024年，兆科眼科在业绩、研发、商业化及出海布局等多方面取得显著进展。公司收入环比增长200% - 270%，年底持有充足现金。研发管线中，低浓度阿托品被国家受理，环孢素眼凝胶与CDE有效沟通，tab014完成三期临床并提交BLA申请，老花眼项目启动二期临床。商业化方面，66个青光眼药物全部获批上市，出海布局拓展至东南亚、澳洲等地区。财务上，2024年亏损同比大幅改善，收入达3,250万，研发开支下降，调整后亏损减少至2亿2,800万，现金流健康。2025年，公司将重点推动青光眼等产品商业化，为2026年重磅产品上市做准备。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.